SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-24-016088
Filing Date
2024-06-07
Accepted
2024-06-07 20:57:22
Documents
1
Period of Report
2024-06-05

Document Format Files

Seq Description Document Type Size
1 form4-06082024_120618.html 4  
1 form4-06082024_120618.xml 4 4007
  Complete submission text file 0001415889-24-016088.txt   6046
Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 450 WEST 15TH STREET, SUITE 505 NEW YORK NY 10011
Business Address C/O INTERCEPT PHARMACEUTICALS, INC. 450 WEST 15TH STREET, SUITE 505 NEW YORK NY 10011 646-747-1000
Benatti Luca (Reporting) CIK: 0001613842 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-38890 | Film No.: 241031289

Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Issuer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)